Login to Your Account



Colby Lands Immunotherapy Platform; $140M to MannKind

By Marie Powers
Staff Writer

Tuesday, November 13, 2012
Privately held Colby Pharmaceutical Co. continued a wave of wheeling and dealing by paying up to $140 million in up-front and milestone payments to MannKind Corp. for disease-specific antigen compounds and intra-lymph node injection (INLI) technologies from its MKC1106 cancer vaccine program.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription